Heron Therapeutics (HRTX) Net Cash Flow (2010 - 2026)

Heron Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 61.27% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 679.85% YoY), and the FY2025 full-year result was $2.8 million, up 198.96% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$2.5 million, up from -$14.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $26.6 million in Q3 2025, with the low at -$35.1 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$3.8 million across 5 years, with a median of -$2.8 million in 2025.
• Annual changes were most pronounced in 2023 — Net Cash Flow soared 1069.87% — and 2025, when it tumbled 23740.98%.
• Heron Therapeutics' Net Cash Flow stood at -$35.1 million in 2022, then soared by 82.37% to -$6.2 million in 2023, then soared by 100.99% to $61000.0 in 2024, then plunged by 23740.98% to -$14.4 million in 2025, then soared by 82.46% to -$2.5 million in 2026.
• The last three Net Cash Flow figures came in at -$2.5 million (Q1 2026), -$14.4 million (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.